-
公开(公告)号：US20130012542A1
公开(公告)日：2013-01-10
申请号：US13618753
申请日：2012-09-14
IPC分类号： C07D413/04 , A61P25/18 , A61K31/454
CPC分类号： A61K31/454 , A61K9/0019 , A61K47/10 , A61K47/26 , A61K47/38
摘要： An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation.
-
公开(公告)号：US20110212141A1
公开(公告)日：2011-09-01
申请号：US13106417
申请日：2011-05-12
IPC分类号： A61K9/14 , A61K31/454 , A61P25/18
CPC分类号： A61K31/454 , A61K9/0019 , A61K47/10 , A61K47/26 , A61K47/38
摘要： An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation.
摘要翻译： 包含具有结构（I）的晶体的可注射贮库制剂，其中R为（FII）且晶体的X 50值为1至200微米。 含有伊立替康或其代谢物晶体的储备制剂具有以下优点：（i）等离子体中晶体的释放可与晶体尺寸相关; （ii）等离子体中的晶体的吸收可以与晶体的大小相关; （iii）可以通过晶体工程和/或研磨来控制晶体的粒度; 和（iv）晶体在储存时是稳定的，并且对灭菌过程如γ辐射是稳定的。
-
公开(公告)号：US08227488B2
公开(公告)日：2012-07-24
申请号：US13401310
申请日：2012-02-21
IPC分类号： A01N43/00 , A01N43/40 , A61K31/553 , A61K31/554 , A61K31/445 , C08J9/28 , C07D211/22 , C07D261/20
CPC分类号： A61K31/454 , A61K9/0019 , A61K47/10 , A61K47/26 , A61K47/38
摘要： An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation.
-
公开(公告)号：US20050250813A1
公开(公告)日：2005-11-10
申请号：US10521064
申请日：2003-07-14
IPC分类号： C07D413/04 , A61K9/10 , A61K31/454 , A61K47/10 , A61K47/14 , A61K47/24 , A61K47/26 , A61K47/34 , A61K47/36 , A61K47/38 , A61P25/28
CPC分类号： A61K31/454 , A61K9/0019 , A61K47/10 , A61K47/26 , A61K47/38
摘要： An injectable depot formulation comprising crystals having Structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolite have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation.
摘要翻译： 包含具有结构（I）的晶体的可注射贮库制剂，其中R为（FII）且晶体的X 50值为1至200微米。 含有伊洛哌啶或其代谢物晶体的储备制剂具有以下优点：（i）等离子体中晶体的释放可与晶体尺寸相关; （ii）等离子体中的晶体的吸收可以与晶体的大小相关; （iii）可以通过晶体工程和/或研磨来控制晶体的粒度; 和（iv）晶体在储存时是稳定的，并且对灭菌过程如γ辐射是稳定的。
-
公开(公告)号：US08293765B2
公开(公告)日：2012-10-23
申请号：US13106417
申请日：2011-05-12
IPC分类号： A01N43/00 , A01N43/40 , A61K31/553 , A61K31/554 , A61K31/445 , C08J9/28 , C07D211/22 , C07D261/20
CPC分类号： A61K31/454 , A61K9/0019 , A61K47/10 , A61K47/26 , A61K47/38
摘要： An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation.
摘要翻译： 包含具有结构（I）的晶体的可注射贮库制剂，其中R为（FII）且晶体的X 50值为1至200微米。 含有伊立替康或其代谢物晶体的储备制剂具有以下优点：（i）等离子体中晶体的释放可与晶体尺寸相关; （ii）等离子体中的晶体的吸收可以与晶体的大小相关; （iii）可以通过晶体工程和/或研磨来控制晶体的粒度; 和（iv）晶体在储存时是稳定的，并且对灭菌过程如γ辐射是稳定的。
-
公开(公告)号：US08614232B2
公开(公告)日：2013-12-24
申请号：US13618753
申请日：2012-09-14
IPC分类号： A61K8/02 , C12Q1/68 , C12Q1/02 , A01N43/00 , A61K31/553 , A61K31/554 , A01N43/40 , A61K31/445
CPC分类号： A61K31/454 , A61K9/0019 , A61K47/10 , A61K47/26 , A61K47/38
摘要： An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation.
摘要翻译： 包含具有结构（I）的晶体的可注射贮库制剂，其中R为（FII）且晶体的X 50值为1至200微米。 含有伊立替康或其代谢物晶体的储备制剂具有以下优点：（i）等离子体中晶体的释放可与晶体尺寸相关; （ii）等离子体中的晶体的吸收可以与晶体的大小相关; （iii）可以通过晶体工程和/或研磨来控制晶体的粒度; 和（iv）晶体在储存时是稳定的，并且对灭菌过程如γ辐射是稳定的。
-
公开(公告)号：US20120156264A1
公开(公告)日：2012-06-21
申请号：US13401310
申请日：2012-02-21
IPC分类号： A61K31/4439 , A61P25/18 , A61K9/00
CPC分类号： A61K31/454 , A61K9/0019 , A61K47/10 , A61K47/26 , A61K47/38
摘要： An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation.
摘要翻译： 包含具有结构（I）的晶体的可注射贮库制剂，其中R为（FII）且晶体的X 50值为1至200微米。 含有伊立替康或其代谢物晶体的储备制剂具有以下优点：（i）等离子体中晶体的释放可与晶体尺寸相关; （ii）等离子体中的晶体的吸收可以与晶体的大小相关; （iii）可以通过晶体工程和/或研磨来控制晶体的粒度; 和（iv）晶体在储存时是稳定的，并且对灭菌过程如γ辐射是稳定的。
-
公开(公告)号：US20090099232A1
公开(公告)日：2009-04-16
申请号：US12254925
申请日：2008-10-21
IPC分类号： A61K31/454
CPC分类号： A61K31/454 , A61K9/0019 , A61K47/10 , A61K47/26 , A61K47/38
摘要： An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation.
摘要翻译： 包含具有结构（I）的晶体的可注射贮库制剂，其中R为（FII）且晶体的X 50值为1至200微米。 含有伊立替康或其代谢物晶体的储备制剂具有以下优点：（i）等离子体中晶体的释放可与晶体尺寸相关; （ii）等离子体中的晶体的吸收可以与晶体的大小相关; （iii）可以通过晶体工程和/或研磨来控制晶体的粒度; 和（iv）晶体在储存时是稳定的，并且对灭菌过程如γ辐射是稳定的。
-
公开(公告)号：US20140363513A1
公开(公告)日：2014-12-11
申请号：US14467212
申请日：2014-08-25
申请人： Markus Ahlheim , Holger Petersen
发明人： Markus Ahlheim , Holger Petersen
CPC分类号： A61K9/0019 , A61K9/14 , A61K9/1647 , A61K9/1694 , A61K38/12 , A61K38/31 , A61K47/10 , A61K47/26 , A61K47/34 , A61K47/38 , A61M5/19 , A61M5/24
摘要： The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).
摘要翻译： 本发明涉及包含奥曲肽或其药学上可接受的盐和两种不同的线性聚丙交酯 - 共 - 乙交酯聚合物（PLGAs）作为活性成分的持续释放制剂。
-
公开(公告)号：US5334710A
公开(公告)日：1994-08-02
申请号：US50941
申请日：1993-04-21
申请人： Markus Ahlheim , Friedrich Lehr
发明人： Markus Ahlheim , Friedrich Lehr
IPC分类号： C07C219/08 , C07C233/16 , C07C245/08 , C07C253/30 , C07C255/58 , C07C255/65 , C07D333/60 , C07D333/64 , C08F20/34 , C08F20/38 , C08F36/04 , C08F36/20 , C09B23/00 , C09B23/01 , C09B29/08 , C09B29/085 , G02F1/361
CPC分类号： C07D333/64 , C07C245/08 , C07C255/65 , C07D333/60 , C08F20/34 , C09B23/0091 , C09B29/0813 , G02F1/3611 , G02F1/3614 , G02F1/3617
摘要： The invention relates to monomeric or polymeric organic compounds having non-linear optical properties, to their production and to their use as electrooptical, photorefractive or holographic devices, especially as modulators, switches, amplifiers, wave guides, sensors to work as sequence transformation especially frequency doubling. These compounds are compounds of Formula I: ##STR1## in which R.sub.1 is a group for formula a ##STR2## or R.sub.1 is a group of formula b ##STR3## or R.sub.1 is an NO.sub.2 where R.sub.1`-R.sub.11 are organic radicals.
摘要翻译： 本发明涉及具有非线性光学性质的单体或聚合物有机化合物，其生产及其作为电光，光折射或全息装置的用途，特别是作为调制器，开关，放大器，波导，用作序列变换的传感器，特别是频率 翻倍 这些化合物是式I的化合物：其中R 1是式a的基团（a）或R 1是式b的基团（b）或R 1是NO 2，其中R 1 '-R11是有机基团。
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.018 秒)
